Keywords Dissociation constants Vortioxetine Spectrophotometric titration REACTLAB SQUAD84 ESAB 1 Introduction Vortioxetine hydrobromide (trade name Brintellix, Trintellix in Canada) with the IUPAC name 1-(2-((2,4-dimethyl-phenyl)thio)phenyl)piperazine hydrobromide, a molecular for- -1 mula of C H N SHBr, and molecular weight of 379.36 gmol , is an atypical antide- 18 22 2 pressant (a serotonin modulator and stimulator) made by Lundbeck  and Takeda . It relieves depression symptoms by increasing serotonin concentrations in the brain, by inhibiting its reuptake in the synapses and by modulating (activating certain receptors while blocking, or antagonizing, others) certain serotonin receptors. This puts it in the class of atypical antidepressants known as serotonin modulators and stimulators [3, 4]. On 30 September 2013 it was approved by the U.S. FDA for the treatment of major depressive disorders in adults. Vortioxetine was also examined as a treatment for generalized anxiety disorder but was not found to be superior to the placebo . Depressive disorders, including major depressive disorders, are common mental health conditions thought to be caused by an imbalance in serotonin (5-HT) and norepinephrine, in addition to having multiple situational, cognitive, and medical factors . The most common side effects reported with
Journal of Solution Chemistry – Springer Journals
Published: May 17, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud